The trajectory of Sildenafil presents a intricate picture for investors. While the initial launch generated substantial profits, the lapse of its exclusive rights opened the floodgates to off-brand competitors, https://indexedbookmarks.com/story21548157/sildenafil-and-pharma-a-volatile-bet